The BALANCE Model The GLP-1 Bridge now runs through December 31, 2027 , overlapping with the BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive Health), which CMS plans to launch in Medicare Part D on January 1, 2027
GLP-1 receptor agonists (GLP-1RAs) like liraglutide and semaglutide, as well as the dual GLP-1 and gastric inhibitory polypeptide (GIP) agonist tirzerpatide are a class of medications that were historically designed to treat type 2 diabetes
Gut Health* Protect Gut Lining &
The available information is too limited to draw conclusions on whether GLP1-RAs increase risks for miscarriage or other pregnancy complications
As a master antioxidant, it protects cells from mercury induced damage
The rectal administration of glutathione may provide a more direct route for the medication to enter the systemic circulation, potentially leading to better bioavailability and efficacy